Plasma apolipoprotein E and XXXX risk: the AIBL study of aging.

@entity1 @entity195 @entity7659 @entity2204
OBJECTIVE: There is mounting evidence for the contribution of @entity2204 to the pathophysiology of @entity195 ( @entity195 ). Studies also indicate that plasma @entity2204 levels may reflect disease status, suggesting that @entity2204 is a potential @entity195 biomarker. However, while some studies of @entity2204 levels in plasma have presented correlations with @entity195 pathology, others have not. Thus, there is a lack of consensus as to the suitability of plasma @entity2204 as an @entity195 biomarker. The major objective of this cross-sectional study was to investigate total plasma @entity2204 as well as levels of the @entity2204 form in a large, highly characterized cohort which included both healthy controls and @entity1 with early-stage @entity195 . METHODS: Total @entity2204 and @entity2204 were measured in 1,079 individuals drawn from the highly characterized Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Total and isoform-specific plasma @entity2204 levels were then compared with cerebral Ab load, as assessed by PET using Pittsburgh compound B ( @entity7659 ). RESULTS: Total @entity2204 and @entity2204 levels were found to be significantly lower in @entity1 with @entity195 in the entire cohort, and decrease with Ab load in the @entity7659 -PET subset. @entity2204 levels were significantly lower among   4 homozygous individuals. In @entity2204 /  4 heterozygote carriers, @entity2204 levels decrease, indicating that @entity2204 levels increase with disease. CONCLUSION: Analysis of cross-sectional data from the AIBL study indicates that plasma @entity2204 levels are altered in @entity195 and correlate with @entity195 pathology level. The significance of these findings will be determined in the AIBL longitudinal study of aging.
